J Bacteriol Virol.  2016 Dec;46(4):319-325. 10.4167/jbv.2016.46.4.319.

Role of Coagulation Factor 2 Receptor during Respiratory Pneumococcal Infections

• Shin SG
• Bong Y
• Lim JH

• KMID: 2366880
• DOI: http://doi.org/10.4167/jbv.2016.46.4.319

Abstract

Coagulation factor 2 receptor (F2R), also well-known as a protease-activated receptor 1 (PAR1), is the first known thrombin receptor and plays a critical role in transmitting thrombin-mediated activation of intracellular signaling in many types of cells. It has been known that bacterial infections lead to activation of coagulation systems, and recent studies suggest that PAR1 may be critically involved not only in mediating bacteria-induced detrimental coagulation, but also in innate immune and inflammatory responses. Community-acquired pneumonia, which is frequently caused by Streptococcus pneumoniae (S. pneumoniae), is characterized as an intra-alveolar coagulation and an interstitial neutrophilic inflammation. Recently, the role of PAR1 in regulating pneumococcal infections has been proposed. However, the role of PAR1 in pneumococcal infections has not been clearly understood yet. In this review, recent findings on the role of PAR1 in pneumococcal infections and possible underlying molecular mechanisms by which S. pneumoniae regulates PAR1-mediated immune and inflammatory responses will be discussed.

Keyword

Streptococcus pneumoniae; Coagulation factor 2 receptor; F2R; Protease-activated receptor 1; PAR1

MeSH Terms

Bacterial Infections
Blood Coagulation Factors*
Inflammation
Negotiating
Neutrophils
Pneumococcal Infections*
Pneumonia
Receptor, PAR-1
Receptors, Thrombin
Streptococcus pneumoniae
Blood Coagulation Factors
Receptor, PAR-1
Receptors, Thrombin

Reference

1). Mizgerd JP. Lung infection–a public health priority. PLoS Med. 2006; 3:e76.

2). Niederman MS. Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Med Clin North Am. 2001; 85:1493–509.

3). Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163:1730–54.

4). Tamayo E, Montes M, Vicente D, Perez-Trallero E. Streptococcus pyogenes Pneumonia in Adults: Clinical Presentation and Molecular Characterization of Isolates 2006–2015. PLoS One. 2016; 11:e0152640.

5). Dockrell DH, Whyte MK, Mitchell TJ. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest. 2012; 142:482–91.

6). Feldman C, Anderson R. Epidemiology, virulence factors and management of the pneumococcus. F1000Res. 2016; 5:2320.

7). O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374:893–902.

8). Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 2007; 27:349–60.

9). Lim JH, Jono H, Koga T, Woo CH, Ishinaga H, Bourne P, et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One. 2007; 2:e1032.

10). Lim JH, Woo CH, Li JD. Critical role of type 1 plasminogen activator inhibitor (PAI-1) in early host defense against nontypeable Haemophilus influenzae (NTHi) infection. Biochem Biophys Res Commun. 2011; 414:67–72.

11). Shin SG, Koh SH, Woo CH, Lim JH. PAI-1 inhibits development of chronic otitis media and tympanosclerosis in a mouse model of otitis media. Acta Otolaryngol. 2014; 134:1231–38.

12). Chambers RC, Scotton CJ. Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc. 2012; 9:96–101.

13). Idell S, Gonzalez K, Bradford H, MacArthur CK, Fein AM, Maunder RJ, et al. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis. 1987; 136:1466–74.

14). Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991; 64:1057–68.

15). Jose R, Williams A, Sulikowski M, Brealey D, Brown J, Chambers R. Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. Lancet. 2015; 385(Suppl 1):S52.

16). Jose RJ, Williams AE, Mercer PF, Sulikowski MG, Brown JS, Chambers RC. Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. J Immunol. 2015; 194:6024–34.

17). Schouten M, van't Veer C, Roelofs JJ, Levi M, van der Poll T. Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care. 2012; 16:R238.

18). Adams MN, Christensen ME, He Y, Waterhouse NJ, Hooper JD. The role of palmitoylation in signalling, cellular trafficking and plasma membrane localization of protease-activated receptor-2. PLoS One. 2011; 6:e28018.

19). Poirier C, O'Brien EP, Bueno Brunialti AL, Chambard J, Swank RT, Guenet J. The gene encoding the thrombin receptor (Cf2r) maps to mouse chromosome 13. Mamm Genome. 1996; 7:322.

20). Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013; 121:431–9.

21). Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal. 2013; 11:86.

22). Shpacovitch V, Feld M, Bunnett NW, Steinhoff M. Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol. 2007; 28:541–50.

23). Weithauser A, Rauch U. Role of protease-activated receptors for the innate immune response of the heart. Trends Cardiovasc Med. 2014; 24:249–55.

24). Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000; 275:6819–23.

25). Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407:258–64.

26). Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol. 2014; 171:1180–94.

27). Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol. 2010; 160:191–203.

28). Holzhausen M, Spolidorio LC, Vergnolle N. Role of protease-activated receptor-2 in inflammation, and its possible implications as a putative mediator of periodontitis. Mem Inst Oswaldo Cruz. 2005; 100(Suppl 1):177–80.

29). Kida Y, Inoue H, Shimizu T, Kuwano K. Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2. Infect Immun. 2007; 75:164–74.

30). Lourbakos A, Potempa J, Travis J, D'Andrea MR, Andrade-Gordon P, Santulli R, et al. Arginine-specific protease from Porphyromonas gingivalis activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. Infect Immun. 2001; 69:5121–30.

31). Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, et al. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood. 2001; 97:3790–97.

32). Asehnoune K, Moine P. Protease-activated receptor-1: key player in the sepsis coagulation-inflammation crosstalk. Crit Care. 2013; 17:119.

33). Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003; 111:25–7.

34). Kager LM, van der Poll T, Wiersinga WJ. The coagulation system in melioidosis: from pathogenesis to new treatment strategies. Expert Rev Anti Infect Ther. 2014; 12:993–1002.

35). Kager LM, Wiersinga WJ, Roelofs JJ, van ‘t Veer C, van der Poll T. Deficiency of protease-activated receptor-1 limits bacterial dissemination during severe Gram-negative sepsis (melioidosis). Microbes Infect. 2014; 160:171–4.

36). Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998; 274:C1429–52.

37). Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004; 84:579–621.

38). Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005; 26:1–43.

39). Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014; 123:2605–13.

40). Bir N, Lafargue M, Howard M, Goolaerts A, Roux J, Carles M, et al. Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol. 2011; 45:632–41.

41). Chung WO, An JY, Yin L, Hacker BM, Rohani MG, Dommisch H, et al. Interplay of protease-activated receptors and NOD pattern recognition receptors in epithelial innate immune responses to bacteria. Immunol Lett. 2010; 131:113–9.

42). Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010; 115:1121–30.

43). Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005; 105:3178–84.

44). Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014; 124:1553–62.

45). Peters T, Henry PJ. Protease-activated receptors and prostaglandins in inflammatory lung disease. Br J Pharmacol. 2009; 158:1017–33.

46). Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, et al. Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem. 2009; 284:28845–55.

47). Rijneveld AW, Weijer S, Florquin S, Speelman P, Shimizu T, Ishii S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis. 2004; 189:711–6.

48). Nylander M, Osman A, Ramstrom S, Aklint E, Larsson A, Lindahl TL. The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets. Thromb Res. 2012; 129:e51–8.

49). de Stoppelaar SF, Bootsma HJ, Zomer A, Roelofs JJ, Hermans PW, van 't Veer C, et al. Streptococcus pneumoniae serine protease HtrA, but not SFP or PrtA, is a major virulence factor in pneumonia. PLoS One. 2013; 8:e80062.

50). Ender M, Andreoni F, Zinkernagel AS, Schuepbach RA. Streptococcal SpeB cleaved PAR-1 suppresses ERK phosphorylation and blunts thrombin-induced platelet aggregation. PLoS One. 2013; 8:e81298.

51). McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci U S A. 2007; 104:5662–7.

52). de Stoppelaar SF, Van't Veer C, van den Boogaard FE, Nieuwland R, Hoogendijk AJ, de Boer OJ, et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost. 2013; 110:582–92.